2018 Oncology Nursing Drug Handbook / Edition 22

by Gail M. Wilkes, Margaret Barton-Burke

Overview

Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah).

Product Details

ISBN-13:	9781284143508
Publisher:	Jones & Bartlett Learning
Publication date:	12/14/2017
Edition description:	Older Edition
Pages:	1712
Product dimensions:	5.50(w) x 8.50(h) x 2.60(d)

About the Author

Oncology Nursing Consultant, Kilauea, Hawaii


Mary Ann Lee Professor of Oncology Nursing, University of Missouri, St. Louis, Research Scientist, Siteman Cancer Center

Table of Contents

Section 1 Cancer Treatment
Chapter 1 Introduction to Chemotherapy Drugs
Chapter 2 Cytoprotective Agents
Chapter 3 Molecular Targeted Therapy
Chapter 4 Immunologic Targeted Therapy
Chapter 5 Chemobiotherapy for Noncancer Diseases
Section 2 Symptom Management
Chapter 6 Pain
Chapter 7 Nausea and Vomiting
Chapter 8 Anorexia and Cachexia
Chapter 9 Anxiety and Depression
Section 3 Complications
Chapter 10 Managing Tumor-Related Skeletal Events and Hypercalcemia
Chapter 11 Infection
Chapter 12 Constipation
Chapter 13 Diarrhea
Appendix 1 Occupational Exposure to Hazardous Drugs
Appendix 2 Common Terminology Criteria for Adverse Events (CTCAE)